Drug Discovery

As AI-generated outputs like safety narrative summaries become part of the official evidentiary record, they face unprecedented scrutiny from global regulatory bodies during the drug approval process. The clinical trial landscape is currently undergoing a massive transformation as generative

The pharmaceutical industry is experiencing a defining transformation as the first patient recently began treatment in the GENESIS-IPF-3 Phase III clinical trial. Academician Nanshan Zhong and President Chang Chen are among the elite medical professionals overseeing the multi-center clinical effort

While immunotherapy was previously confined to treating advanced stages of the disease, new evidence shows its efficacy in earlier, resectable settings. Gastric cancer has long remained a formidable opponent within the global oncology landscape, currently ranking as the fifth most common cancer

The traditional labor-intensive process of utilizing high-resolution imaging and biochemical assays to map binding sites often spans several years. This bottleneck has long hindered the pace of pharmaceutical innovation, forcing researchers to rely on trial-and-error methods that consume vast

Although lamotrigine is a staple treatment for bipolar disorder and epilepsy, it triggers a dangerous systemic immune response in approximately one out of every thousand patients. Known as Stevens-Johnson Syndrome, this reaction causes severe skin detachment and organ damage. For years, doctors

The integration of proteomic aging clocks represents a fundamental shift in how the pharmaceutical industry approaches the treatment of chronic decay. For decades, the pursuit of longevity-enhancing therapies was throttled by the absence of a reliable, unified metric of biological age, forcing